Clinical Trial Update: A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The update describes a Phase 1/2 trial evaluating a combination of Zarnestra (tipifarnib) with Velcade (bortezomib) for relapsed multiple myeloma, which has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)
• ZARNESTRA

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED